| News

Qnami secures investment of 4 million Swiss francs

17.05.2021

Qnami has raised a total of 4 million Swiss francs from investors after successfully closing a Series A financing round. The Basel Area-based startup has developed a quantum microscope technology that has since been patented as well as producing the first commercial quantum microscope.

qnami team
The Qnami team with CEO Mathieu Munsch (fourth from left) (Img: Qnami)

Qnami has announced the successful closing of a Series A financing round in which the startup raised a total of 4 million Swiss francs in fresh capital. Qnami was founded in Basel in 2017 and is now based in Muttenz in the canton of Basel-Landschaft.

The financing round was led by the venture capitalists Runa Capital, which operates out of headquarters in both Silicon Valley and Europe, as well as SIT Capital, which is associated with the Schaffhausen Institute of Technology. The circle of investors included the venture capital companies Quantonation and Verve Ventures, which operate on a pan-European basis, in addition to the Bonn-based High-Tech Gründerfonds and the Cantonal Bank of Zurich.

With this fresh capital injection, Qnami intends to extend its patented quantum microscope technology into applications that will facilitate the design and production of quantum computers and spintronics devices. Furthermore, according to the press release issued by the company, the funds will be used to scale the market launch of the Qnami ProteusQ, the first commercial quantum microscope.

This device uses Qnami’s patented Quantilever diamond scanning probes. “We have gained good market traction with the launch of the ProteusQ and Quantilevers in the materials research setting”, explains Mathieu Munsch, co-founder and CEO of Qnami. “Top researchers already use Qnami’s technology to discover and describe the magnetic properties of new materials”, he adds.

According to Dmitry Galperin, General Partner at Runa Capital, the company is of the view that the technology could also be used for additional applications, including medical imaging and navigation, for example. Galperin is set to join the board of Qnami as a new member.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Botanikind settles in Basel
Basel Area Business & Innovation, Innovation, Invest

Botanikind settles in Basel

The internationally active Swiss company Botanikind has settled in Basel and established Botanikind AG there. It provides natural ingredients for...

Read More
Kinarus secures capital commitment of 57 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest

Kinarus secures capital commitment of 57 million Swiss francs

The biopharmaceutical company Kinarus has signed a capital commitment of up to 57 million Swiss francs with the investment group...

Read More
Biotech startups from the Basel Area confirm leading position
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Biotech startups from the Basel Area confirm leading position

As part of the Top 100 Swiss Startup Awards 2021, the most promising startups in Switzerland are honored. These also...

Read More
T3 Pharma wins Swiss Economic Award
Basel Area Business & Innovation, Innovation, Invest

T3 Pharma wins Swiss Economic Award

T3 Pharma has won the Swiss Economic Award 2021. Switzerland’s most prestigious young entrepreneur prize is awarded by the Swiss...

Read More
Worg selects Basel Area for European headquarters
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Worg selects Basel Area for European headquarters

Worg Pharmaceuticals has opted to establish its European headquarters at the site Allschwil of the Switzerland Innovation Park Basel Area....

Read More
ten23 health settles in Basel
Basel Area Business & Innovation, Innovation, Invest

ten23 health settles in Basel

The life sciences cluster Rosental Mitte located in Basel is home to a new, globally active company called ten23 health....

Read More
1 2 3 48

Do you have a question? We'd like to hear from you.